CA2524034A1 - Utilisations de composes modulant les canaux ioniques - Google Patents
Utilisations de composes modulant les canaux ioniques Download PDFInfo
- Publication number
- CA2524034A1 CA2524034A1 CA002524034A CA2524034A CA2524034A1 CA 2524034 A1 CA2524034 A1 CA 2524034A1 CA 002524034 A CA002524034 A CA 002524034A CA 2524034 A CA2524034 A CA 2524034A CA 2524034 A1 CA2524034 A1 CA 2524034A1
- Authority
- CA
- Canada
- Prior art keywords
- ion channel
- channel modulating
- hydrogen
- subject
- modulating compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46715903P | 2003-05-02 | 2003-05-02 | |
US60/467,159 | 2003-05-02 | ||
US49339203P | 2003-08-07 | 2003-08-07 | |
US60/493,392 | 2003-08-07 | ||
US51624803P | 2003-10-31 | 2003-10-31 | |
US51648603P | 2003-10-31 | 2003-10-31 | |
US60/516,248 | 2003-10-31 | ||
US60/516,486 | 2003-10-31 | ||
US52691103P | 2003-12-03 | 2003-12-03 | |
US60/526,911 | 2003-12-03 | ||
US52716903P | 2003-12-04 | 2003-12-04 | |
US60/527,169 | 2003-12-04 | ||
US52825103P | 2003-12-08 | 2003-12-08 | |
US60/528,251 | 2003-12-08 | ||
US54494104P | 2004-02-13 | 2004-02-13 | |
US60/544,941 | 2004-02-13 | ||
US55940504P | 2004-04-01 | 2004-04-01 | |
US60/559,405 | 2004-04-01 | ||
PCT/US2004/013731 WO2004098525A2 (fr) | 2003-05-02 | 2004-05-03 | Utilisations de composes modulant les canaux ioniques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2524034A1 true CA2524034A1 (fr) | 2004-11-18 |
Family
ID=33437324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002524034A Abandoned CA2524034A1 (fr) | 2003-05-02 | 2004-05-03 | Utilisations de composes modulant les canaux ioniques |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2524034A1 (fr) |
WO (1) | WO2004098525A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE260240T1 (de) | 1998-04-01 | 2004-03-15 | Nortran Pharmaceuticals Inc | Aminocyclohexylverbindungen und deren verwendung |
US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
US7524879B2 (en) | 2000-10-06 | 2009-04-28 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
ATE325789T1 (de) | 2003-05-02 | 2006-06-15 | Cardiome Pharma Corp | Aminocyclohexylether-verbindungen und deren verwendung |
US7345086B2 (en) | 2003-05-02 | 2008-03-18 | Cardiome Pharma Corp. | Uses of ion channel modulating compounds |
US7674820B2 (en) | 2003-08-07 | 2010-03-09 | Cardiome Pharma Corp. | Ion channel modulating activity I |
US7345087B2 (en) | 2003-10-31 | 2008-03-18 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
CA2561733A1 (fr) * | 2004-04-01 | 2005-10-13 | Cardiome Pharma Corp. | Derives de composes de modulation des canaux ioniques, compositions pharmaceutiques et utilisations |
US7977373B2 (en) | 2004-04-01 | 2011-07-12 | Cardiome Pharma Corp. | Prodrugs of ion channel modulating compounds and uses thereof |
US8058304B2 (en) | 2004-04-01 | 2011-11-15 | Cardiome Pharma Corp. | Merged ion channel modulating compounds and uses thereof |
US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
US8263638B2 (en) * | 2004-11-08 | 2012-09-11 | Cardiome Pharma Corp. | Dosing regimens for ion channel modulating compounds |
JP5159314B2 (ja) * | 2004-11-18 | 2013-03-06 | カーディオム ファーマ コーポレイション | アミノシクロヘキシルエーテル化合物の合成方法 |
EP1915340B1 (fr) | 2005-06-15 | 2013-08-07 | Cardiome Pharma Corp. | Procedes synthetiques de preparation de composes d'ether aminocyclohexyle |
EP2462933A1 (fr) * | 2007-05-04 | 2012-06-13 | Cardiome Pharma Corp. | Formulations orales à libération contrôlée de composés de modulation de canal ionique et procédés associés pour empêcher l'arythmie |
WO2009018547A1 (fr) * | 2007-08-01 | 2009-02-05 | Cardiome Pharma Corp. | Formulations à libération prolongée pour la prévention d'arythmies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268590A1 (fr) * | 1999-04-12 | 2000-10-12 | Nortran Pharmaceuticals Inc. | Composes de regulation des canaux ioniques et utilisations de ces produits |
-
2004
- 2004-05-03 WO PCT/US2004/013731 patent/WO2004098525A2/fr active Search and Examination
- 2004-05-03 CA CA002524034A patent/CA2524034A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004098525A3 (fr) | 2005-04-14 |
WO2004098525A9 (fr) | 2005-01-20 |
WO2004098525A2 (fr) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8188140B2 (en) | Uses of ion channel modulating compounds | |
US7687536B2 (en) | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics | |
CA2524034A1 (fr) | Utilisations de composes modulant les canaux ioniques | |
EP1087934B1 (fr) | Composes d'aminocyclohexyl ether et leurs applications | |
US20050154009A1 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | |
KR20160108611A (ko) | 심방세동의 치료 방법 | |
US7057053B2 (en) | Ion channel modulating compounds and uses thereof | |
EP2501381B1 (fr) | Traitement de la fibrillation atriale | |
JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
RU2213560C2 (ru) | Фармацевтическая композиция, содержащая сочетание правовращающего и левовращающего изомеров соталола | |
CA2370834C (fr) | Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression | |
US20090041841A1 (en) | Controlled release tablet formulations for the prevention of arrhythmias | |
CA2720410A1 (fr) | Utilisation d'une combinaison d'udenafil et d'alfuzosine ou d'oxybutynine dans le traitement d'une vessie hyperactive | |
KR100352898B1 (ko) | 새로운3-벤조일-3,7-디아자바이사이클로[3,3,1]노난-화합물을함유하는약제 | |
EP1868598B1 (fr) | Schemas posologiques pour modulateurs de canaux ioniques pour le traitement de la fibrillation auriculaire aigue chez l'homme | |
RU2358732C2 (ru) | Жидкие фармацевтические композиции, содержащие производные 3,7-диазабицикло(3,3,1)нонана, для лечения антиаритмических реакций | |
CA2533492A1 (fr) | Utilisation de composes de 3,7-diazabicyclo[3,3,1]nonane pour traiter et/ou prevenir des evenements arythmiques chez des patients humains males | |
MXPA05011808A (en) | Uses of ion channel modulating compounds | |
EA028995B1 (ru) | Соль тезофензина и оптически активных ацетиламинокислот, их применение для лечения и/или профилактики нарушений, связанных с ожирением | |
US20050054667A1 (en) | Method of treating or inhibiting anti-arrhythmic events in male human patients | |
JP2002255819A (ja) | 神経栄養因子的作用剤 | |
ZA200300220B (en) | Compounds for the treatment of addictive disorders. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |
Effective date: 20190503 |